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Abstract
Aims: To investigate the relationship between hyperuricemia (HUA) and the clinical backgrounds in Japanese patients with
type 2 diabetes mellitus.
Methods: After a cross-sectional study evaluating the association of HUA with the clinical characteristics in 1,213 patients
with type 2 diabetes mellitus, the estimated glomerular filtration rate (eGFR) and the incidence of diabetic
macroangiopathies was investigated in a prospective observational study in 1,073 patients during a 3.5 year period.
HUA was defined by serum uric acid levels .327 mmol/L or as patients using allopurinol.
Results: The frequency of HUA was significantly higher in the diabetic patients (32% in men and 15% in women) than in the
normal controls (14% in men and 1% in women). In total, HUA was found in 299 (25%) of the patients during the cross-
sectional study. Even after adjusting for sex, drinking status, treatment for diabetes mellitus, body mass index, hypertension,
use of diuretics, hyperlipidemia, HbA1c and/or the eGFR, the HUA was independently associated with some diabetic
complications. The eGFR was significantly reduced in HUA patients compared to those with normouricemia in the 12
months after observation was started. HUA was also an independent risk factor for coronary heart disease even after
adjustment in the Cox proportional hazard model.
Conclusions: HUA is a associated with diabetic micro- and macroangiopathies. HUA is a predictor of coronary heart disease
and renal dysfunction in patients with type 2 diabetes mellitus. However, the influence of HUA is considered to be limited.
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Introduction
It has been reported that hyperuricemia (HUA) is an independent
risk factor for the progression of renal dysfunction [1,2] and
cardiovascular events [1–10], as well as gout. Type 2 diabetes
mellitus is also well-known as a major risk factor for chronic kidney
disease (CKD) and atherosclerotic disease. Although the serum uric
acidlevel waspreviously shown to be higherinpatients with diabetes
mellitus than in the population without glucose intolerance [10], it
was also elevated in the individuals with impaired glucose tolerance
other than type 2 diabetes [11–14]. However, HUA has been
reported to be associated with the onset of diabetes mellitus or
metabolicsyndrome[15–20].Althoughseveralstudieshavereported
the relationship between HUA and diabetic macroangiopathies,
suchascoronary heartdisease, strokeand peripheral arterial disease,
the conclusions have been controversial [21–27]. Furthermore, the
changes in kidney function associated with the HUA have not yet
been sufficiently studied in the patients with type 2 diabetes mellitus.
The aim of this study was to investigate the relationship between
the HUA and the clinical background including diabetic
complications and the glomerular filtration rate (GFR), in a
cross-sectional study, and to determine the incidences of diabetic
macroangiopathies and the changes in the eGFR according to a
prospective observational study in Japanese patients with type 2
diabetes mellitus.
Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The Ethics Committees of
Edogawa Hospital approved the protocol of this study and waived
the need for written informed consent because the data were
analyzed anonymously for this observation study based on the data
stored in the hospital database.
Study population and methods
First, a cross-sectional study was performed in a population of
1,213 patients diagnosed with type 2 diabetes mellitus who
underwent consecutive evaluations, including urinalysis, and
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Department of Diabetes, Metabolism and Kidney Disease of
Edogawa Hospital, Tokyo, Japan between April 2008 and March
2009. The patients with end-stage renal disease receiving
maintenance dialysis were excluded from this study. Subjects
who underwent physical health examinations were also entered
into the study as normal controls (age-matched, 156 men and 116
women). The control did not have diabetes mellitus or a history of
myocardial and/or cerebral infarction.
Second, a prospective observational study was performed in the
population of the cross-sectional study. The estimated GFR
(eGFR) and new onset of diabetic micro- and macroangiopathies
were estimated in 1,073 of the patients with type 2 diabetes
mellitus who were treated for more than one year. All of the
indications for anti-diabetic, anti-hypertensive and anti-hyperlip-
idemic agents were determined by each patient’s physician during
the observation period. The patients visited our hospital once
every 1 to 4 months and the mean follow-up period was 2868
months.
The eGFR was calculated using the formula reported by
Matsuo et al [28]. This equation originated from the MDRD study
group [29] arranged for Japanese individuals, and it is recom-
mended by the Japanese Society of Nephrology: eGFR (mL/min/
1.73 m
2) =1946Scr
21.0946Age
20.28760.739 (if female). The
urinary albumin excretion (UAE) is presented as the albumin-to-
creatinine ratio (ACR; mg/g creatinine). The ACR was staged
according to an analysis of a spot urine sample as: stage I
(normoalbuminuria), ACR,30 mg/g creatinine; stage II (micro-
albuminuria), 30#ACR,300 mg/g creatinine; stage III (macro-
albuminuria), ACR$300 mg/g creatinine (or dipstick urinalysis
revealed 2+,3 + or 4+) and eGFR$ 30 mL/min/1.73 m
2; and
stage IV, ACR$ 300 mg/gcreatinine (or dipstick urinalysis
revealed 2+,3 + or 4+) and eGFR,30 mL/min/1.73 m
2. Diabetic
nephropathy included stages II, III and IV. Any individuals who
had additional kidney diseases, such as acute renal failure and
chronic glomerulonephritis, were excluded from this study.
The obese and non-obese individuals were defined as those
having a BMI $ 25 kg/m
2 and a BMI ,25 kg/m
2, respectively.
The blood pressure was measured twice with the subjects in the
sitting position after a 5 minute rest. The lower value of the two
measurements was used for the study. Hypertension was defined as
a systolic blood pressure$140 mmHg and/or a diastolic blood
pressure$90mmHg. The participants currently using antihyper-
tensive medications were also classified as positive for hypertension.
The serum total cholesterol, LDL-cholesterol, HDL-cholesterol
and uric acid concentrations were measured with a TBA-200 FR
NEO using Determiner L TC II, Determiner L LDL-C,
Determiner L HDL-C and Determiner L UA instruments (Kyowa
Medex Co., Ltd., Tokyo, Japan). Hyperlipidemia was defined by
serum concentrations of total cholesterol $5.7 mmol/L, LDL-
cholesterol levels $3.6 mmol/L, or as patients who were already
undergoing treatment with lipid-lowering agents. The triglyceride
concentrations were not investigated in this study because fasting
blood samples could not always be obtained for measurements.
HUA was defined by serum uric acid levels .327 mmol/L or as
patients using allopurinol according to the guidelines proposed by
the Japanese Society of Gout and Nucleic Acid Metabolism [30].
The HbA1c levels were determined by a high performance liquid
chromatography method using an automated HLC-723G7
analyzer (Tosoh Corporation, Tokyo, Japan) and calibrated by
the Japan Diabetes Society (JDS) standard calibrators. The value
for HbA1c (%) is estimated as a National Glycohemoglobin
Standardization Program (NGSP) equivalent value (%) calculated
by the formula: HbA1c = HbA1c (JDS) + 0.4, considering the
relational expression of HbA1c (JDS) measured by the previous
Japanese standard substance and measurement methods and
HbA1c (NGSP) [31].
Diabetic retinopathy was defined as simple, pre-proliferative and
proliferative retinopathy judged according to the results of a
funduscopic examination performed by expert ophthalmologists.
Diabetic neuropathy was diagnosed by the presence of two or more
components among clinical symptoms (bilateral spontaneous pain,
hypoesthesia, or paraesthesia of the legs), the absence of ankle
tendon reflexes and decreased vibration sensations using a C128
tuning fork according to the guidelines published by the JDS [32].
Cerebrovascular disease was diagnosed by the physicians as a
history of an ischemic stroke using brain computed tomography or
magneticresonanceimaging.Onlythepatientswithsymptomswere
classified as having cerebrovascular disease, and cases of silent brain
infarction, transient ischemic attack and brain hemorrhage were
excluded from this study. Coronary heart disease was diagnosed
based on a previous history of myocardial infarction, angina
pectoris, electrocardiogram abnormalities suggesting myocardial
ischemia or interventions after coronary angiographic examination.
Peripheral arterial disease was diagnosed by the absence of a pulse
in the legs along with ischemic symptoms, obstructive findings on
ultrasonographic or angiographic examinations of the lower
extremities, or an ankle-brachial pressure index (ABI) ,0.9.
The ABI and brachial-ankle pulse wave velocity (baPWV) as
indicators of atherosclerosis were measured using a Form PWV/
ABI, BP-203PRE II instrument (Omron Colin Co., Ltd, Bunkyo,
Tokyo, Japan). The intima-media thickness (IMT) of the carotid
artery was measured via ultrasonographic examinations by skilled
laboratory technicians using an Aplio XV ultrasound machine
(Toshiba Medical Systems Corp., Ohtawara, Tochigi, Japan) as
described previously [33].
Statistical methods
All data are shown as the means 6 SD. An analysis of variance
(ANOVA) and the x2 test were used for between-group
comparisons of the continuous and categorical variables, respec-
tively. A multiple logistic regression analysis was performed to
determine the association of HUA with the other clinical
parameters. Odds ratios (OR) and respective 95% confidence
intervals (95% CI) were determined to examine the strength of the
relationship between the HUA and the prevalence of diabetic
micro- and macroangiopathies. The cumulative incidence of
diabetic macroangiopathies was estimated by the Kaplan-Meier
method, and the differences were assessed with the log-rank test.
We used the Cox proportional hazard model to estimate the
hazard ratio (HR) of HUA along with the 95% CI. Differences of
P,0.05 (two-tailed) were considered to be statistically significant.
The statistical software package JMP, version 8.0 (SAS Institute,
Cary, NC, USA), was used to perform all of the analyses.
Results
The mean uric acid concentration was not significantly different
between the study subjects (321683 mmol/L in men and 286671
mmol/L in women) and normal controls (333671 mmol/L in men
and 274648 mmol/L in women). However, the frequency of HUA
was significantly higher in the patients (32% in men and 15% in
women) than in the normal controls (14% in men and 1% in
women, P,0.01). In total, HUA was found in 299 (25%) of the
patients with type 2 diabetes mellitus. Allopurinol was adminis-
tered to 273 of the patients with HUA. None of the patients
received probenecid, benzbromarone and/or febuxostat for the
treatment of HUA.
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parameters of the patients. Table 2 shows a comparison of clinical
parameters between the groups with and without HUA. HUA was
significantly more common in men, drinkers, obese subjects and
those with hypertension than in those without. Patients receiving
insulin or diuretic treatments also were more likely to have HUA,
while those with hyperlipidemia were less likely to have HUA. The
levels of HbA1c, serum HDL-cholesterol, creatinine, eGFR, and
ABI were significantly lower in the subjects with HUA than in
Table 1. The clinical characteristics of the patients.
%/
Mean ± SD
Number
estimated (%)
Age (years) 64612 1213 (100)
Men 59 1213 (100)
Duration of diabetes mellitus (years) 10610 935 (77)
Current plus past smoking 59 780 (64)
Drinkers
# 43 888 (73)
Treatment for diabetes mellitus
Diet only/OHA/insulin 11/60/29 1213 (100)
Body mass index (kg/m
2) 24.764.1 1192 (98)
Obesity
## 42 1192 (98)
Hypertension 73 1213 (100)
Anti-hypertensive agents 1213 (100)
ACEi 12
ARB 43
CCB 41
Diuretics 10
Hyperlipidemia 65 1212 (10)
HbA1c (%) 7.861.8 1122 (93)
Total cholesterol (mmol/L) 5.161.1 1119 (92)
LDL-cholesterol (mmol/L) 3.060.9 647 (53)
HDL-cholesterol (mmol/L) 1.560.5 816 (67)
Serum creatinine (mmol/L) 85647 1213 (100)
Estimated GFR (mL/min/1.73 m
2)5 3 619 1213 (100)
CKD stage 1213 (100)
Stage 1+23 2
Stage 3 59
Stage 4+59
Serum uric acid (mmol/L) 307681 1213 (100)
Diabetic retinopathy
$ 41 889 (73)
Diabetic neuropathy 75 864 (71)
Diabetic nephropathy 111 (92)
Stage I 60
Stage II 18
Stage III+IV 21
Cerebrovascular disease 14 1208 (100)
Coronary heart disease 22 1209 (100)
Peripheral arterial disease 5 1211 (100)
ABI 1.160.1 636 (52)
baPWV (cm/s) 17696398 633 (52)
Carotid IMT (mm) 1.060.3 359 (30)
OHA: oral hypoglycemic agents, ACEi: angiotensin-converting enzyme inhibitor,
ARB: angiotensin II receptor blocker, CCB: calcium channel blocker, GFR:
glomerular filtration rate, CKD: chronic kidney disease, ABI: ankle-brachial index,
baPWV: brachial-ankle pulse wave velocity, and IMT: intima-media thickness
#Drinkers were defined as those who consumed more than 20 g/day of ethanol.
##Obesity was considered to be present in individuals with a body mass index
$25 kg/m
2.
$Diabetic retinopathy includes simple, pre-proliferative, and proliferative
retinopathies.
doi:10.1371/journal.pone.0027817.t001
Table 2. A comparison of the clinical parameters between
groups without and with hyperuricemia.
%/Mean ± SD
Normouricemia Hyperuricemia P
(n=914) (n=299)
Age (years) 64612 65612 0.34
Men 54 76 ,0.01
Duration of diabetes mellitus
(years)
10610 11610 0.09
Current plus past smoking 58 61 0.55
Drinkers
# 41 50 0.02
Treatment for diabetes mellitus
Diet only/OHA/insulin 11/63/26 10/52/38 ,0.01
Body mass index (kg/m
2) 24.464.0 25.764.4 ,0.01
Obesity
## 39 52 ,0.01
Hypertension 69 87 ,0.01
Use of diuretics 4 27 ,0.01
Hyperlipidemia 67 59 0.01
HbA1c (%) 7.961.9 7.661.7 0.03
Total cholesterol (mmol/L) 5.161.0 5.061.2 0.10
LDL-cholesterol (mmol/L) 3.060.9 3.061.0 0.41
HDL-cholesterol (mmol/L) 1.660.1 1.460.4 ,0.01
Serum creatinine (mmol/L) 71627 115680 ,0.01
Estimated GFR (mL/min/1.73 m
2)6 0 617 40617 ,0.01
CKD stage ,0.01
Stage 1+24 0 9
Stage 3 57 64
Stage 4+53 2 7
Serum uric acid (mmol/L) 283664 378685 ,0.01
Diabetic retinopathy
$ 37 54 ,0.01
Diabetic nephropathy
$$ 33 64 ,0.01
Diabetic neuropathy 74 75 0.19
Cerebrovascular disease 12 19 ,0.01
Coronary heart disease 20 27 ,0.01
Peripheral arterial disease 4 7 0.01
ABI 1.1160.11 1.0860.15 ,0.01
baPWV (cm/s) 17476357 18356506 0.02
Carotid IMT (mm) 1.060.2 1.060.3 0.89
OHA: oral hypoglycemic agents, ACEi: angiotensin-converting enzyme inhibitor,
ARB: angiotensin II receptor blocker, CCB: calcium channel blocker, GFR:
glomerular filtration rate, CKD: chronic kidney disease, ABI: ankle-brachial index,
baPWV: brachial-ankle pulse wave velocity, and IMT: intima-media thickness
#Drinkers were defined as those who consumed more than 20 g/day of ethanol.
##Obesity was considered to be present in individuals with a body mass index
$25 kg/m
2.
$Diabetic retinopathy includes simple, pre-proliferative, and proliferative
retinopathies.
$$Diabetic nephropathy includes ACR stages II, III, and IV.
doi:10.1371/journal.pone.0027817.t002
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HUA. Diabetic retinopathy and nephropathy were more common
in the patients with HUA than in those without. Diabetic
macroangiopathies were also frequently found in the subjects with
HUA.
The odd ratios for diabetic micro- and macroangiopathies with
HUA as determined by a logistic regression analysis are shown in
Table 3. HUA was significantly associated with diabetic
angiopathies, excluding neuropathy. However, HUA was associ-
ated with only diabetic retinopathy and nephropathy after
adjustment for sex, drinking status, treatment for diabetes mellitus,
body mass index, hypertension, use of diuretics, hyperlipidemia,
HbA1c and/or the eGFR.
Table 4 shows the baseline characteristics of the patients with
type 2 diabetes mellitus for the prospective observation study. The
mean serum uric acid concentration was 303677 mmol/L, and
HUA was found in 202 (32%) of men and 60 (14%) of women.
Allopurinol was administered to 246 patients with HUA.
Figure 1 shows the changes of the eGFR in patients without
and with HUA. The eGFR was significantly reduced in the
patients with HUA compared to those without HUA in during the
12 months after the observation was started.
The incidence of diabetic macroangiopathies in the groups
without and with HUA is shown in Figure 2. Although HUA did
not affect the incidence of CVD (HR 1.28, [95% CI 0.63–2.42],
log-rank test, P=0.46) and PAD (HR 1.76, [95% CI 0.59–4.79],
log-rank test, P=0.27), it was a significant risk factor for CHD (HR
2.60 [95% CI 1.11–5.92], log-rank test, P=0.02).
In the Cox proportional hazard models, HUA was an
independent risk factor (HR 2.81 [95% CI 1.00–7.81], P=0.049)
for coronary heart disease even after adjustment for sex, drinking
status, treatment for diabetes mellitus, body mass index,
hypertension, hyperlipidemia and the eGFR.
Discussion
In the present study, the frequency of HUA was significantly
higher in the patients with type 2 diabetes mellitus than in the
normal subjects. The prevalence of HUA in patients with type 2
diabetes varied in the previous reports [10–14]. Fang et al.
described that the serum uric acid level was higher in diabetic
women than in non-diabetic women, although it was not different
between diabetic and non-diabetic men, according to the National
Health and Nutrition Examination Survey in the USA [10]. On
the other hand, it was reported that HUA was more common in
Table 3. The odds ratios for the diabetic micro- and
macroangiopathies in patients with hyperuricemia
determined by the logistic regression analyses.
Wald x2 score OR (95% CI) P
Unadjusted
Retinopathy
$ 21.6 2.06 (1.52–2.79) ,0.01
Nephropathy
$$ 77.9 3.75 (2.80–5.04) ,0.01
Neuropathy 1.7 1.28 (0.89–1.86) 0.19
CVD 9.4 1.73 (1.21–2.45) ,0.01
CHD 6.6 1.49 (1.10–2.01) 0.01
PAD 4.2 1.80 (1.01–3.14) 0.04
Adjusted (model 1)
Retinopathy
$ 3.3 1.50 (0.97–2.33) 0.07
Nephropathy
$$ 13.2 2.12 (1.42–3.19) ,0.01
Neuropathy 2.3 0.69 (0.40–1.13) 0.13
CVD 0.2 0.89 (0.51–1.50) 0.66
CHD 2.0 0.71 (0.45–1.13) 0.15
PAD 0.0 1.00 (0.38–2.48) 0.99
Adjusted (model 2)
Retinopathy
$ 5.5 1.65 (1.09–2.51) 0.02
Nephropathy
$$ 27.1 2.79 (1.90–4.12) ,0.01
Neuropathy 1.1 0.77 (0.48–1.27) 0.30
CVD 0.0 0.97 (0.58–1.59) 0.90
CHD 0.2 0.90 (0.58–1.37) 0.61
PAD 0.3 1.27 (0.52–2.93) 0.58
Adjusted (model 3)
Retinopathy
$ 3.8 1.66 (0.99–2.78) 0.05
Nephropathy
$$ 23.4 3.40 (2.08–5.62) ,0.01
Neuropathy 0.5 0.80 (0.44–1.47) 0.46
CVD 0.1 0.90 (0.43–1.79) 0.76
CHD 0.5 0.81 (0.46–1.41) 0.47
PAD 1.1 1.72 (0.83–2.90) 0.29
CVD: cerebrovascular disease, CHD: coronary heart disease, PAD: peripheral
arterial disease
$Diabetic retinopathy includes simple, pre-proliferative, and proliferative
retinopathies.
$$Diabetic nephropathy includes ACR stages II, III, and IV.
Model 1 was adjusted for sex, drinking status, treatment for diabetes mellitus,
body mass index, hypertension, use of diuretics, hyperlipidemia, HbA1c and the
eGFR.
Model 2 was adjusted for sex, drinking status, treatment for diabetes mellitus,
body mass index, use of diuretics, hyperlipidemia and HbA1c.
Model 3 was adjusted for age, sex, duration of diabetes, smoking status,
drinking status, treatment for diabetes mellitus, body mass index, use of
diuretics, hyperlipidemia and HbA1c.
doi:10.1371/journal.pone.0027817.t003
Table 4. The baseline characteristics of the patients
evaluated in the observation study.
%/Mean ± SD
Number
estimated (%)
Age (years) 64612 1073 (100)
Men 59 1073 (100)
Drinkers
# 43 888 (73)
Body mass index (kg/m
2) 24.764.0 1054 (98)
Obesity
## 42 1054 (98)
Hypertension 73 1073 (100)
Hyperlipidemia 66 1072 (10)
HbA1c (%) 7.761.7 994 (93)
Serum creatinine (mmol/L) 80644 1073 (100)
Estimated GFR (mL/min/1.73 m
2)5 4 618 1073 (100)
Serum uric acid (mmol/L) 303677 1073 (100)
Cerebrovascular disease 14 1070 (100)
Coronary heart disease 22 1070 (100)
Peripheral arterial disease 5 1073 (100)
GFR: glomerular filtration rate.
#Drinkers were defined as those who consumed more than 20 g/day of ethanol.
##Obesity was considered to be present in individuals with a body mass index
$25 kg/m
2.
doi:10.1371/journal.pone.0027817.t004
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diabetes mellitus or normal subjects [11–13]. Alderman et al.
reported that the serum uric acid concentration was not associated
with the presence of diabetes mellitus [14], and Wen et al.
described that it was negatively correlated with the blood glucose
level in a population of 484,568 subjects in Taiwan [3]. Li et al also
reported inverse correlations of the blood glucose and HbA1c
levels with the serum uric acid concentration in patients with type
2 diabetes mellitus [34]. In the present study, the HbA1c level was
also lower in patients with HUA than in those without, and it was
negatively correlated with the serum uric acid concentration
(HbA1c=20.17 x uric acid level + 8.33, univariate analysis,
P,0.01). Although these results seem to be conflicting, it is clear
that HUA is a risk factor for diabetes mellitus and/or metabolic
syndrome [15–20]. The discrepancies in the studies are considered
to be caused by the effects of insulin on the renal proximal tubules.
As a likely mechanism linking HUA and diabetes mellitus/
metabolic syndrome, it is known that hyperinsulinemia reduces the
urinary excretion of uric acid by activating the transporter of uric
acid (URAT), which is expressed in the proximal tubules of the
kidneys [35,36]. Exogenous insulin also suppresses urinary uric
acid excretion [37,38]. Although the serum insulin or C-peptide
concentration was not evaluated in the present study, frequent
insulin treatment (29%) in addition to the presence of obesity
(42%), which is often present in patients with endogenous
hyperinsulinemia, may have increased the prevalence of HUA in
our study group. Therefore, body mass index and insulin use of the
study subjects should be considered when the prevalence of HUA
is discussed in patients with type 2 diabetes mellitus.
The relationship between vascular diseases and HUA in patients
with type 2 diabetes has not been fully explored. In our cross-
sectional study, HUA was associated with diabetic micro- and
macroangiopathies, as well as the ABI and baPWV, which are
surrogate markers for atherosclerosis (Table 2). Furthermore, the
incidence of coronary heart disease was significantly higher in the
patients with HUA than in those without during the follow-up
observation period (Figure 2). Rathmann et al. reported that
HUA was associated with coronary heart disease in 4,047 patients
with type 2 diabetes mellitus according to a cross-sectional study
[21]. Several other investigators have described elevated serum
uric acid to be a risk factor for atherosclerotic disease in patients
with diabetes mellitus [22–26]. In contrast, Ong et al. recently
reported that the serum uric acid level did not predict
cardiovascular mortality in 1,268 patients with type 2 diabetes in
western Australia [27]. All of these studies determined the
incidence of vascular events after dividing the subjects into tertiles,
quartiles or quintiles according to their initial level of serum uric
acid. In the present study, subjects were divided into two groups
that were independent other than their uric acid levels. When
allopurinol was used, an individual was defined as having HUA
even if the serum uric acid level was within the normal range.
Therefore, our study investigated the association between diabetic
complications and the existence of HUA, but not the serum uric
acid levels. Our data suggested that HUA clearly predicted the
incidence of diabetic macroangiopathies in the patients with type 2
diabetes mellitus, but that its influence was limited. However, the
relatively short duration of follow-up in our study might have led
us to underestimate the incidence of vascular events, even though
our study included a large number of patients.
It has been established that hyperuricemia is an independent
risk factor for the progression of renal dysfunction [1,2]. However,
the influence of HUA on the renal functions has been insufficiently
investigated in patients with diabetes mellitus. In the present study,
the eGFR significantly decreased in the patients with HUA
compared with those without. Tseng et al. [39] and Fukui et al. [40]
reported that the serum uric acid level was elevated, along with
increased urinary albumin excretion in the smaller study
population with type 2 diabetes using a cross-sectional design. Li
et al. [31] revealed that the level of serum uric acid was negatively
correlated with the eGFR in 1,026 Chinese patients with type 2
diabetes mellitus. However, our study is the first report investigate
the changes in the eGFR between diabetic patients without and
with HUA. It is considered to be important that a significant
difference in the glomerular function between the two groups was
observed within one year after observation was started.
The ABI, baPWV and carotid IMT are known to be surrogate
markers for atherosclerosis. They show abnormal values in
patients with type 2 diabetes mellitus, as we previously reported
[33,40]. In the present study, the ABI was significantly lower and
baPWV was higher in the patients with HUA than in those
Figure 1. The changes in the eGFR in the patients with and without hyperuricemia. The data represent the means 6 SD. Open and closed
circles represent the values in normouricemic and hyperuricemic individuals, respectively. * P,0.05 and ** P,0.01 vs. 0 month. # ,0.01 vs.
normouricemia.
doi:10.1371/journal.pone.0027817.g001
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between the serum uric acid concentration and the ABI and
carotid IMT in patients with type 2 diabetes [41]. Therefore, the
HUA may reflect subclinical atherosclerosis, as well as previously
diagnosed macroangiopathies, in patients with type 2 diabetes
mellitus. Intensive examination to detect the vascular complica-
tions might be valuable in the clinic when HUA is found in
patients with type 2 diabetes mellitus.
The present study has several important limitations. First, the
follow-up period was relatively short compared to other studies.
The number of patients decreased by nearly one-third at 36
months. This might cause us to underestimate the incidence of
diabetic macroangiopathies. Second, the initial level of the eGFR
was different between the groups without and with HUA. The
levels should be similar in order to clarify the deterioration of the
eGFR in the subjects with HUA and type 2 diabetes mellitus.
Third, it was impossible to evaluate the effect of allopurinol
administration for the normalization of the uric acid level, because
allopurinol was used in most of the patients with HUA in our
study. Recently, an anti-atherogenic effect of allopurinol was
reported in patients with angina pectoris [42]. Therefore, future
studies should closely examine the difference between patients
treated with allopurinol and those who are untreated. Fourth, we
did not evaluate the course of the serum uric acid levels and
changes in the anti-diabetic, anti-hyperlipidemic and anti-
hypertensive agents administered during the observation period.
Changes in the levels of serum uric acid, blood glucose, lipids and
blood pressure might therefore have affected the incidence of
diabetic macroangiopathies in the present study. Fifth, the number
of controls in this study was relatively small. Therefore, there may
have been some selection bias. Sixth, the frequency of peripheral
arterial disease seems to be low compared to the frequencies of
cerebrovascular and coronary heart diseases. This might have
been due to the small number of the patients who underwent ABI
as a screening test. The underestimation of the prevalence and
new onset of peripheral arterial disease should be considered for
both the cross-sectional and the observational studies.
In conclusion, HUA is associated with diabetic micro- and
macroangiopathies. Furthermore, HUA is a predictor of coronary
heart disease and renal dysfunction in patients with type 2 diabetes
mellitus. However, the influence of HUA was considered to be
limited in our study during the relatively short observation period.
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